使用生存网络荟萃分析比较奈莫利珠单抗与其他可用的特异性全身治疗药物治疗特应性皮炎的效果。

Living network meta-analysis to compare nemolizumab against other available targeted systemic treatments for atopic dermatitis.

作者信息

Drucker Aaron M, Walwyn Chantel, Chu Cherry, Yiu Zenas Z N, Rochwerg Bram, Di Giorgio Sonya, Arents Bernd W M, Mohan Tanya, Burton Tim, Spuls Phyllis I, Schmitt Jochen, Prieto-Merino David, Flohr Carsten

机构信息

Division of Dermatology, Department of Medicine, University of Toronto, Toronto, ON, Canada.

Department of Medicine and Women's College Research Institute, Women's College Hospital, Toronto, ON, Canada.

出版信息

Br J Dermatol. 2025 Aug 18;193(3):548-552. doi: 10.1093/bjd/ljaf166.

DOI:10.1093/bjd/ljaf166

PMID:40334148

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12360034/

Abstract

Nemolizumab is a new biologic approved to treat atopic dermatitis. In this perspective piece, we use results from our living systematic review and network meta-analysis to provide perspective on the relative efficacy of nemolizumab compared with other approved targeted systemic treatments.

摘要

奈莫利珠单抗是一种被批准用于治疗特应性皮炎的新型生物制剂。在这篇观点文章中，我们利用实时系统评价和网状Meta分析的结果，对奈莫利珠单抗与其他已批准的靶向全身治疗药物相比的相对疗效提供见解。